Form 4: Vericel Corp Director Exercises Options and Sells Shares Under 10b5-1 Plan

Robert Zerbe, a director at Vericel Corp, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• Robert Zerbe, a director at Vericel Corp, executed transactions involving the company's stock on November 22, 2024.
• He exercised options to acquire 2,500 shares of common stock at a price of $13.05 per share.
• Concurrently, he sold 2,500 shares of common stock at a price of $60 per share.
• These transactions were conducted under a pre-established Rule 10b5-1 trading plan adopted on March 12, 2024.
• Following these transactions, Zerbe directly owns 26,595 shares of common stock and options to purchase 10,000 shares.

Sentiment

Score: 5

Explanation: The document reflects routine insider transactions under a pre-arranged plan, indicating a neutral sentiment.

Industry Context

This is a routine filing for a director's stock transactions and is common practice for corporate insiders. The use of a 10b5-1 plan is a common way to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a standard practice among corporate insiders to manage their stock transactions and avoid potential insider trading issues.
• The reported transactions are typical for directors who receive stock options as part of their compensation.
• Similar filings are regularly made by directors and officers of publicly traded companies like Amgen, Regeneron, and Biogen, who also use 10b5-1 plans.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are part of a pre-arranged trading plan.

Key Dates

Keywords

Vericel Corp, Robert Zerbe, stock options, share sale, Rule 10b5-1, insider trading, director transaction